| Sep 12 |
Neurocrine ending development of luvadaxistat amid failed study
|
| Sep 12 |
Neurocrine Biosciences Provides Update on ERUDITE™ Phase 2 Data for Luvadaxistat in Adults with Cognitive Impairment Associated with Schizophrenia
|
| Sep 10 |
Neurocrine Biosciences to Participate at the 2024 Cantor Global Healthcare Conference
|
| Sep 2 |
Nxera wins $35m after Phase II schizophrenia trial success
|
| Sep 2 |
Dollar General, Temu Parent PDD And Super Micro Computer Are Among Top 10 Large Cap Losers Last Week (Aug 25-Aug 31): Are The Others In Your Portfolio?
|
| Aug 30 |
Why Neurocrine Biosciences Stock Was Tumbling This Week
|
| Aug 29 |
Neurocrine Biosciences' Lower Dose Data Puts Its Schizophrenia Candidate In The Game, Analyst Upgrades Stock
|
| Aug 29 |
Neurocrine Stock Down 19% on Mixed Schizophrenia Study Results
|
| Aug 29 |
Neurocrine upped to overweight by Piper, sees '568 as still viable
|
| Aug 29 |
Neurocrine reports positive data from Phase II schizophrenia treatment trial
|
